Dopamine agonists are indicated for the treatment of early, moderate and advanced stages of Parkinson’s disease (PD) as well as for the alleviation of levodopa-related motor complications. They can be subdivided into ergoline and non-ergoline derivatives. Dopamine antagonists are typically taken orally. However, apomorphine is usually delivered subcutaneously and rotigotine is available as a transdermal patch. There are an important number of side effects associated with dopamine antagonists, including nausea, hallucinations and heart valve fibrosis. More information about dopamine antagonists can be found on the EPDA website.